



## Personalized Medicine in Lung Cancer: Diagnosis, Treatment and Prognosis

Guest Editor:

**Dr. Athina N. Markou**

Department of Chemistry,  
National and Kapodistrian  
University of Athens, 15771  
Athens, Greece

Deadline for manuscript  
submissions:  
**closed (31 March 2022)**

### Message from the Guest Editor

Lung cancer is the most common cause of cancer-related mortality worldwide. Although new therapeutic strategies are defined according to the molecular profile of the tissue, a high rate of these targeted therapies fail to cure the disease because of several biological and technological challenges, mainly the heterogeneity of the tumor. The purpose of this Special Issue, *Personalized Medicine in Lung Cancer: Diagnosis, Treatment and Prognosis*, is to highlight: 1) the benefit of personalized medicine in the diagnosis, treatment, and prognosis of lung cancer patients; 2) the new assays that could achieve high sensitivity for early detection of minimal residual disease (MRD) in lung cancer patients; 3) the crucial role of liquid biopsies in personalized medicine in lung cancer; and 4) the spatial heterogeneity as well as temporal heterogeneity between the primary tumor and local or distant recurrences in the same patient. Finally, we also wish to present the rapid development of technology and drugs in this area of research.

Dr. Athina N. Markou  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Kenneth P.H. Pritzker**

Department of Laboratory  
Medicine and Pathobiology,  
Department of Surgery,  
University of Toronto, 6 Queens  
Pk Crescent W.F, Toronto, ON  
M5S 3H2, Canada

## Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, PubMed, PMC, Embase, and other databases.

**Journal Rank:** CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)